In its push to backstop sales of blockbuster Soliris, Alexion has touted its better-than-expected success at switching patients to follow-up drug Ultomiris. But if switching to the newer med is going ...
Even as a war of words is being waged in the U.S. over escalating drug prices, Canada has been battling with Alexion ($ALXN) over the $700,000 cost of rare-disease ...
A simmering battle in Canada over the cost of a rare disease drug took a new twist as a government entity ended talks with the manufacturer because it failed to agree on evidence for justifying the ...
Smarting from a patent defeat for cash cow Soliris in Europe, Alexion has dulled the pain with a phase 3 readout that sets up new filings for follow-up Ultomiris. The top-line data comes from a study ...
A heated clash over drug pricing is unfolding this week in Canada where Alexion Pharmaceuticals is challenging how the government attempts to control excessive prices. The battle is actually the ...
Soliris (eculizumab) is a prescription drug that’s used to treat certain rare autoimmune conditions. Soliris is given as an intravenous (IV) infusion by a doctor or other healthcare professional.
The FDA approved a fourth indication for Alexion Pharmaceuticals’ brand-name eculizumab (Soliris) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are ...
After she was told to prepare for the worst, a Middletown woman was given new life by medicine that is so rare — and expensive — interns aren’t allowed to handle it. Now, Lisa Gose and her husband, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback